Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: A phase 2, randomized, doseranging, single-oral dose evaluation

Clinical Infectious Diseases

Volumn 67, Issue 4, 2018, Pages 504-512

  Taylor, Stephanie N ^a   Morris, David H ^b   Avery, Ann K ^c   Workowski, Kimberly A ^d   Batteiger, Byron E ^e   Tiffany, Courtney A ^f   Perry, Caroline R ^f   Raychaudhuri, Aparna ^f   Scangarella Oman, Nicole E ^f   Hossain, Mohammad ^f   Dumont, Etienne F ^f  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Desert AIDS Project   (United States)

^c METROHEALTH MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f GLAXOSMITHKLINE   (United States)

Author keywords

Gepotidacin; Gonorrhea; Neisseria gonorrhoeae; Urogenital

Indexed keywords

CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; GEPOTIDACIN; PENICILLIN DERIVATIVE; SPECTINOMYCIN; TETRACYCLINE; ACENAPHTHENE DERIVATIVE; ANTIINFECTIVE AGENT; FUSED HETEROCYCLIC RINGS;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIARRHEA; DISEASE ERADICATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; ERUCTATION; FATIGUE; FEMALE; FLATULENCE; GENE MUTATION; GONORRHEA; GROUPS BY SEX; HOT FLUSH; HUMAN; HYPERHIDROSIS; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; NEISSERIA GONORRHOEAE; PHASE 2 CLINICAL TRIAL; PREMEDICATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; UROGENITAL TRACT INFECTION; ADOLESCENT; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECT; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHARYNX DISEASE; RECTUM DISEASE; UROGENITAL TRACT DISEASE; YOUNG ADULT;

ACENAPHTHENES; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FEMALE UROGENITAL DISEASES; GONORRHEA; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MALE UROGENITAL DISEASES; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEISSERIA GONORRHOEAE; PHARYNGEAL DISEASES; RECTAL DISEASES; YOUNG ADULT;

EID: 85049511835     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy145     Document Type: Article

References (34)

1. World Health Organization. WHO guidelines for the treatment of Neisseria gon-orrhoeae. 2016. Available at: http://apps.who.int/iris/bitstream/10665/246114/1/9789241549691-eng.pdf?ua=1. Accessed 21 March 2017.
2. Centers for Disease Control and Prevention. Sexually transmitted diseases surveillance 2016. Atlanta, GA: CDC, 2017. Available at: https://www.cdc.gov/std/stats16/CDC-2016-STDS-Report-for508WebSep21-2017-1644.pdf. Accessed 12 October 2017.
3. European Centre for Disease Prevention and Control. Annual epidemiological report 2016-gonorrhea. Stockholm, Sweden: ECDC, 2016. Available at: https://ecdc.europa.eu/sites/portal/files/documents/Gonorrhoea%20AER-0.pdf. Accessed 25 July 2017.
4. Hook E W, Handsfield HH. Gonococcal infections in the adult. In: Holmes KK, Sparling P F, Stamm WE, et al. eds. Sexually transmitted diseases. 4th ed. New York: McGraw-Hill, 2008:627-45.
5. Unemo M, Shafer WM. Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future. Clin Microbiol Rev 2014; 27:587-613.
6. Kirkcaldy RD, Ballard RC, Dowell D. Gonococcal resistance: are cephalosporins next? Curr Infect Dis Rep 2011; 13:196-204.
7. Unemo M, Golparian D, Nicholas R, Ohnishi M, Gallay A, Sednaoui P. High-level cefixime-and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure. Antimicrob Agents Chemother 2012; 56:1273-80.
8. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gono-coccal infection. N Engl J Med 2012; 366:485-7.
9. Ohnishi M, Golparian D, Shimuta K, et al. Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: Detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother 2011; 55:3538-45.
10. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7:1401-22.
11. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Atlanta, GA: CDC, 2013. Available at: https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 31 May 2017.
12. Centers for Disease Control and Prevention. Gonorrhea treatment guidelines: revised guidelines to preserve last effective treatment option. Atlanta, GA: CDC, 2013. Available at: https://www.cdc.gov/std/treatment/2010/gonorrhea-treatment-guidelines-factsheet.pdf. Accessed 20 March 2017.
13. Kirkcaldy RD, Harvey A, Papp JR, et al. Neisseria gonorrhoeae antimicrobial susceptibility surveillance-the Gonococcal Isolate Surveillance Project, 27 sites, United States, 2014. MMWR Surveill Summ 2016; 65:1-19.
14. Alirol E, Wi TE, Bala M, et al. Multidrug-resistant gonorrhea: a research and development roadmap to discover new medicines. PLoS Med 2017; 14:e1002366.
15. Bignell C, Unemo M; European STI Guidelines Editorial Board. 2012 European guideline on the diagnosis and treatment of gonorrhoea in adults. Int J STD AIDS 2013; 24:85-92.
16. Workowski KA, Bolan GA; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep 2015; 64:1-137.
17. Cole MJ, Spiteri G, Jacobsson S, et al. Overall low extended-spectrum cephalo-sporin resistance but high azithromycin resistance in Neisseria gonorrhoeae in 24 European countries, 2015. BMC Infect Dis 2017; 17:617.
18. Katz AR, Komeya AY, Kirkcaldy RD, et al. Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016. Clin Infect Dis 2017; 65:918-23.
19. Soge OO, Harger D, Schafer S, et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azith-romycin (Portland, OR, 2011). Sex Transm Dis 2012; 39:877-9.
20. Lefebvre B, Martin I, Demczuk W, et al. Ceftriaxone-resistant Neisseria gonor-rhoeae, Canada, 2017. Emerg Infect Dis 2018. Available at: https://wwwnc.cdc. gov/eid/article/24/2/17-1756-article. Accessed 29 November 2017.
21. Hook EW 3rd, Golden M, Jamieson BD, et al. A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea. Clin Infect Dis 2015; 61:1043-8.
22. Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gen-tamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea. Clin Infect Dis 2014; 59:1083-91.
23. Taylor SN, Marrazzo J, Batteiger B, et al. A phase II trial of single-dose oral ETX0914 (AZD0914) for treatment of uncomplicated urogenital gonorrhea [abstract 5B5]. 2016 STD Prevention Conference (Atlanta). Sex Transm Dis 2016; 43:S147.
24. Bax BD, Chan PF, Eggleston DS, et al. Type IIA topoisomerase inhibition by a new class of antibacterial agents. Nature 2010; 466:935-40.
25. Biedenbach DJ, Bouchillon SK, Hackel M, et al. In vitro activity of gepotida-cin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens. Antimicrob Agents Chemother 2016; 60:1918-23.
26. Negash K, Andonian C, Felgate C, et al. The metabolism and disposition of GSK2140944 in healthy human subjects. Xenobiotica 2016; 46:683-702.
27. Tiffany CA, Hossain M, McDonald M, et al. Safety and pharmacokinetics of single escalating oral doses of GSK2140944, a novel bacterial topoisomerase inhibitor [abstract F-1218]. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (Denver). American Society for Microbiology, 2013. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=5a00e178-5200-4888-bd14-54df807b1a86&cKey=e2bf6c2c-ce55-4645-97c2-085165aba0d2&mKey=7dd36e88-52c3-4ff1-a5df-1d00766558b8. Accessed 20 July 2017.
28. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. Safety and pharmacokinetics of single escalating IV doses of GSK2140944, a novel bacterial topoisomerase inhibitor [abstract F-277]. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2014. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=018d4f7b-adbb-4284-a1a7-bd3dacc88b1c&cK-ey=65c91e81-a211-4b2c-ba1d-fccfd39dd938&mKey=5d6b1802-e453-486b-bcbb-b11d1182d8bb. Accessed 20 July 2017.
29. Tiffany CA, Hossain M, McDonald M, Lerman S, Dumont EF. Safety and pharma-cokinetics of repeat escalating IV doses of GSK2140944, a novel bacterial topoisomer-ase inhibitor [abstract F-278]. Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 2014. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?sKey=018d4f7b-adbb-4284-a1a7-bd3dacc88b1c&cKey=22532b0d-62d2-4c64-b47c-2856992644d4&m-Key=5d6b1802-e453-486b-bcbb-b11d1182d8bb. Accessed 20 July 2017.
30. Farrell DJ, Sader HS, Rhomberg PR, Scangarella-Oman NE, Flamm RK. In vitro activity of gepotidacin (GSK2140944) against Neisseria gonorrhoeae. Antimicrob Agents Chemother 2017; 61:e02047-16.
31. Scangarella-Oman N, Hossain M, Dixon P, et al. P2.38 Microbiological analysis from a phase ii study in adults evaluating single doses of gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea caused by Neisseria gonorrhoeae. Sex Transm Infect 2017; 93:A84-5.
32. Clopper C, Pearson S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934; 26:404-13.
33. Hossain M, Zhou M, Tiffany C, Dumont E, Darpo B. A phase I, randomized, double-blinded, placebo-and moxifloxacin-controlled, four-period crossover study to evaluate the effect of gepotidacin on cardiac conduction as assessed by 12-lead electrocardiogram in healthy volunteers. Antimicrob Agents Chemother 2017; 61:e02385-16.
34. Lyss SB, Kamb ML, Peterman TA, et al; Project RESPECT Study Group. Chlamydia trachomatis among patients infected with and treated for Neisseria gonorrhoeae in sexually transmitted disease clinics in the United States. Ann Intern Med 2003; 139:178-85.